Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Review

The bidirectional interation between pancreatic cancer and diabetes

Authors: Junhui Li, Gang Cao, Qingyong Ma, Han Liu, Wei Li, Liang Han

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

The bidirectional interation between pancreatic cancer (PanCa) and diabetes has been confirmed by epidemiological studies, which provide evidence-based medical support for further research into the mechanisms involved in the interaction. We reviewed the literature regarding the role of diabetes in the generation and progression of PanCa and the mechanism by which PanCa induces diabetes for its malignant progression. The effect of antidiabetic drugs on the occurrence and prognosis of PanCa was also reviewed. Diabetes may directly promote the progression of PanCa by pancreatic duct enlargement and hypertension, as well as by enabling an increased tumor volume. Hyperinsulinemia, insulin resistance, cytokines, hyperglycemia and genotype change are also important factors in the progression of PanCa with diabetes. Hyperglycemia may be the first clinical manifestation and is helpful in the early diagnosis of PanCa. Furthermore, antidiabetic drugs can have different effects on the occurrence and prognosis of PanCa. The bidirectional interation between PanCa and diabetes is involved in the occurrence, proliferation, invasion, metastasis and prognosis of PanCa with diabetes. The discovery of biomarkers for the early diagnosis of PanCa, as well as the novel usage of metformin for its antitumor effects and determining the potential mechanisms of these effects, may be the next direction for PanCa research and treatment.
Literature
1.
2.
Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA, Jemal A, Ward E, Plescia M, Ries LA, Edwards BK: Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012, 118: 2338-2366. 10.1002/cncr.27514.PubMedCentralCrossRefPubMed
3.
Grote VA, Becker S, Kaaks R: Diabetes mellitus type 2 - an independent risk factor for cancer?. Exp Clin Endocrinol Diabetes. 2010, 118: 4-8. 10.1055/s-0029-1243193.CrossRefPubMed
4.
Huxley R, Ansary-Moghaddam A, Berrington De-González A, Barzi F, Woodward M: Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005, 92: 2076-2083. 10.1038/sj.bjc.6602619.PubMedCentralCrossRefPubMed
5.
Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT: Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 2011, 22: 189-197. 10.1007/s10552-010-9686-3.CrossRefPubMed
6.
Ogunleye AA, Ogston SA, Morris AD, Evans JM: A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer. 2009, 101: 1199-1201. 10.1038/sj.bjc.6605240.PubMedCentralCrossRefPubMed
7.
Magruder JT, Elahi D, Andersen DK: Diabetes and pancreatic cancer: chicken or egg?. Pancreas. 2011, 40: 339-351. 10.1097/MPA.0b013e318209e05d.CrossRefPubMed
8.
Johnson JA, Bowker SL, Richardson K, Marra CA: Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011, 54: 2263-2271. 10.1007/s00125-011-2242-1.CrossRefPubMed
9.
Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, Calderon R, Friedlander Y, Paltiel O, Harlap S: Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med. 2007, 5: 25-31. 10.1186/1741-7015-5-25.PubMedCentralCrossRefPubMed
10.
Tseng CH: New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer. Pancreas. 2012, Jun. [Epub ahead of print]
11.
Ogawa Y, Tanaka M, Inoue K, Yamaguchi K, Chijiiwa K, Mizumoto K, Tsutsu N, Nakamura Y: A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002, 94: 2344-2349. 10.1002/cncr.10493.CrossRefPubMed
12.
Hong SG, Jung SJ, Joo MK, Lee BJ, Yeon JE, Park JJ, Byun KS, Bak YT: Prevalence of pancreatic cancer in diabetics and clinical characteristics of diabetes-associated with pancreatic cancer-comparison between diabetes with and without pancreatic cancer. Korean J Gastroenterol. 2009, 54: 167-173. 10.4166/kjg.2009.54.3.167.CrossRefPubMed
13.
Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM: Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005, 129: 504-511.PubMedCentralCrossRefPubMed
14.
Jamal MM, Yoon EJ, Vega KJ, Hashemzadeh M, Chang KJ: Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroenterol. 2009, 15: 5274-5278. 10.3748/wjg.15.5274.PubMedCentralCrossRefPubMed
15.
Stevens RJ, Roddam AW, Beral V: Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007, 96: 507-509. 10.1038/sj.bjc.6603571.PubMedCentralCrossRefPubMed
16.
Saruç M, Karaarslan M, Rasa K, Saygili O, Ince U, Baysal C, Pour PM, Cakmakçi M, Tözün N: Pancreatic cancer and glucose metabolism. Turk J Gastroenterol. 2009, 20: 257-260.
17.
18.
Wang F, Gupta S, Holly EA: Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1458-1463. 10.1158/1055-9965.EPI-06-0188.CrossRefPubMed
19.
Aggarwal G, Rabe KG, Petersen GM, Chari ST: New-onset diabetes in pancreatic cancer: a study in the primary care setting. Pancreatology. 2012, 12: 156-161.PubMedCentralCrossRefPubMed
20.
Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J: Is profound peripheral insulin resistance in patients with PaC caused by a tumor-associated factor?. Am J Surg. 1993, 165: 61-67. 10.1016/S0002-9610(05)80405-2.CrossRefPubMed
21.
Kuang TT, da Jin Y, Wang DS, Xu XF, Ni XL, Wu WC, Lou WH: Clinical epidemiological analysis of the relationship between pancreatic cancer and diabetes mellitus: data from a single institution in China. J Dig Dis. 2009, 10: 26-29. 10.1111/j.1751-2980.2008.00359.x.CrossRefPubMed
22.
Matsubayashi H, Maeda A, Kanemoto H, Uesaka K, Yamazaki K, Hironaka S, Miyagi Y, Ikehara H, Ono H, Klein A, Goggins M: Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. Pancreas. 2011, 40: 974-978. 10.1097/MPA.0b013e3182156e1b.CrossRefPubMed
23.
Bartsch DK, Kress R, Sina-Frey M, Grutzmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, Witzigmann H, Pridohl O, Ghadimi M, Horstmann OV, Berndorff W, Jochimsen L, Schmidt J, Eisold S, Estevez-Schwarz L, Hahn SA, Schulmann K, Bock W, Gress T, Zugel N, Breitschaft K, Prenzel K, Messmann H, Endlicher E, Schneider M, Ziegler A: Prevalence of familial pancreatic cancer in Germany. Int J Cancer. 2004, 110: 902-906. 10.1002/ijc.20210.CrossRefPubMed
24.
Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA: Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003, 124: 1292-1299. 10.1016/S0016-5085(03)00272-5.CrossRefPubMed
25.
Uni W, Shelly N, Richard Z: Pancreatic adenocarcinoma (PA) and diabetes mellitus (DM). Gastroenterology. 2010, 138: S-553.
26.
Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC: Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia. 2010, 53: 21-26. 10.1007/s00125-009-1556-8.PubMedCentralCrossRefPubMed
27.
Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, Adrian TE, Pour PM: Prevention of PaC induction in hamsters by metformin. Gastroenterology. 2001, 120: 1263-1270. 10.1053/gast.2001.23258.CrossRefPubMed
28.
Liu J, Knezetic JA, Strömmer L, Permert J, Larsson J, Adrian TE: The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin End Met. 2000, 85: 1232-1238. 10.1210/jc.85.3.1232.
29.
Permert J, Herrington M, Kazakoff K, Pour PM, Adrian TE: Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog Carcinog Mutagen. 2001, 21: 59-67. 10.1002/1520-6866(2001)21:1<59::AID-TCM6>3.0.CO;2-V.CrossRefPubMed
30.
Krechler T, Jachymova M, Pavlikova M, Vecka M, Zeman M, Krska Z, Svestka T, Zak A: Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study. Neoplasma. 2009, 56: 26-32. 10.4149/neo_2009_01_26.CrossRefPubMed
31.
Pantalone D, Ragionieri I, Nesi G: Improved survival in small pancreatic cancer. Dig Surg. 2001, 18: 41-46. 10.1159/000050095.CrossRefPubMed
32.
Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, Galloway JR, Adsay NV, Jacobs S, Kooby DA: Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2010, 17: 502-513. 10.1245/s10434-009-0789-6.CrossRefPubMed
33.
Fisher WE, McCullough PJ, Ray MB, Rogers DH, Bell RH: Diabetes enhances growth of pancreatic carcinoma cells. Surgery. 1988, 104: 431-436.PubMed
34.
Dong X, Li Y, Chang P, Tang H, Hess KR, Abbruzzese JL, Li D: Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prev Res (Phila). 2011, 4: 758-766. 10.1158/1940-6207.CAPR-10-0247.CrossRef
35.
Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH: The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer. 2006, 37: 139-145.PubMed
36.
Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M: Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995, 55: 2007-2011.PubMed
37.
Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D: Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2008, 17: 3467-3473. 10.1158/1055-9965.EPI-08-0514.PubMedCentralCrossRefPubMed
38.
Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D: Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010, 139: 464-473. 10.1053/j.gastro.2010.04.042. 473.e1-3PubMedCentralCrossRefPubMed
39.
Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valerio A, Navaglia F, Zambon CF, Falda A, Pedrazzoli S, Plebani M: Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause?. Clin Chim Acta. 2006, 372: 120-128. 10.1016/j.cca.2006.03.027.CrossRefPubMed
40.
Basso D, Greco E, Padoan A, Fogar P, Scorzeto M, Fadi E, Bozzato D, Moz S, Navaglia F, Zambon CF, Seraglia R, De Carlo E, Valerio A, Reggiani C, Pedrazzoli S, Plebani M: Altered intracellular calcium fluxes in pancreatic cancer induced diabetes mellitus: relevance of the S100A8 N-terminal peptide (NT-S100A8). J Cell Physiol. 2011, 226: 456-468. 10.1002/jcp.22355.CrossRefPubMed
41.
Zhou L, Zhang R, Wang L, Shen S, Okamoto H, Sugawara A, Xia L, Wang X, Noguchi N, Yoshikawa T, Uruno A, Yao W, Yuan Y: Upregulation of REG Ialpha accelerates tumor progression in pancreatic cancer with diabetes. Int J Cancer. 2010, 127: 1795-1803. 10.1002/ijc.25188.CrossRefPubMed
42.
Tingstedt B, Johansson P, Andersson B, Andersson R: Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol. 2007, 42: 754-759. 10.1080/00365520601058452.CrossRefPubMed
43.
Fogar P, Basso D, Pasquali C, Piva MG, Brigato L, De Paoli M, Galeotti F, Corsini A, Plebani M: Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer. Clin Chim Acta. 1998, 277: 181-189. 10.1016/S0009-8981(98)00125-9.CrossRefPubMed
44.
Basso D, Millino C, Greco E, Romualdi C, Fogar P, Valerio A, Bellin M, Zambon CF, Navaglia F, Dussini N, Avogaro A, Pedrazzoli S, Lanfranchi G, Plebani M: Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut. 2004, 53: 1159-1166. 10.1136/gut.2003.024471.PubMedCentralCrossRefPubMed
45.
Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y: Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology. 2001, 48: 1577-1578.PubMed
46.
Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y: Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology. 2004, 51: 928-930.PubMed
47.
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414: 813-820. 10.1038/414813a.CrossRefPubMed
48.
Busik JV, Hootman SR, Greenidge CA, Henry DN: Glucosespecific regulation of aldose reductase in capan-1 human pancreatic duct cells in vitro. J Clin Invest. 1997, 100: 1685-1692. 10.1172/JCI119693.PubMedCentralCrossRefPubMed
49.
Li W, Ma Q, Li J, Guo K, Liu H, Han L, Ma G: Hyperglycemia enhances the invasive and migratory activity of pancreatic cancer cells via hydrogen peroxide. Oncol Rep. 2011, 25: 1279-1287.PubMed
50.
Sindhu RK, Koo JR, Roberts CK, Vaziri ND: Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: response to insulin and antioxidant therapies. Clin Exp Hypert. 2004, 26: 43-53. 10.1081/CEH-120027330.CrossRef
51.
Cullen JJ, Weydert C, Hinkhouse MM, Ritchie J, Domann FE, Spitz D, Oberley LW: The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res. 2003, 63: 1297-1303.PubMed
52.
Cullen JJ, Mitros FA, Oberley LW: Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. Pancreas. 2003, 26: 23-27. 10.1097/00006676-200301000-00005.CrossRefPubMed
53.
Suzuki K, Islam KN, Kaneto H, Ookawara T, Taniguchi N: The contribution of fructose and nitric oxide to oxidative stress in hamster islet tumor (HIT) cells through the inactivation of glutathione peroxidase. Electrophoresis. 2000, 21: 285-288. 10.1002/(SICI)1522-2683(20000101)21:2<285::AID-ELPS285>3.0.CO;2-5.CrossRefPubMed
54.
Veit C, Genze F, Menke A, Hoeffert S, Gress TM, Gierschik P, Giehl K: Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res. 2004, 64: 5291-5300. 10.1158/0008-5472.CAN-04-1112.CrossRefPubMed
55.
Takahashi M: The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001, 12: 361-373. 10.1016/S1359-6101(01)00012-0.CrossRefPubMed
56.
Liu H, Ma QY, Li JH: High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol Cell Biochem. 2011, 347: 95-101. 10.1007/s11010-010-0617-0.CrossRefPubMed
57.
Han L, Ma Q, Li J, Liu H, Li W, Ma G, Xu Q, Zhou S, Wu E: High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One. 2011, 6: e27074-10.1371/journal.pone.0027074.PubMedCentralCrossRefPubMed
58.
Li JH, Ma QY: Hyperglycemia promotes the perineural invasion in pancreatic cancer. Med Hypotheses. 2008, 71: 386-389. 10.1016/j.mehy.2008.05.001.CrossRefPubMed
59.
Li J, Ma Q, Liu H, Guo K, Li F, Li W, Han L, Wang F, Wu E: Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One. 2011, 6: e17385-10.1371/journal.pone.0017385.PubMedCentralCrossRefPubMed
60.
Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM, Chari ST: Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol. 2009, 104: 2318-2325. 10.1038/ajg.2009.253.PubMedCentralCrossRefPubMed
61.
Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM: Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008, 134: 95-101. 10.1053/j.gastro.2007.10.040.PubMedCentralCrossRefPubMed
62.
Pannala R, Basu A, Petersen GM, Chari ST: New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009, 10: 88-95. 10.1016/S1470-2045(08)70337-1.PubMedCentralCrossRefPubMed
63.
Centers for Disease Control and Prevention: National Diabetes Fact Sheet. 2007
64.
Park HY, Song SY, Cho HC, Lee KH, Lee KT, Lee JK: Clinical characteristics of pancreatic cancer-associated new onset diabetes. Gastroenterology. 2010, 138: 1391-
65.
Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group: Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994, 331: 81-84. 10.1056/NEJM199407143310203.CrossRefPubMed
66.
Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, Chari ST: Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas. 2011, 40: 768-772. 10.1097/MPA.0b013e318220816a.PubMedCentralCrossRefPubMed
67.
Chen HF, Chen P, Li CY: Risk of malignant neoplasm of the pancreas in relation to diabetes: a population-based study in Taiwan. Diabetes Care. 2011, 34: 1177-1179. 10.2337/dc10-2006.PubMedCentralCrossRefPubMed
68.
Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST: Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008, 134: 981-987. 10.1053/j.gastro.2008.01.039.PubMedCentralCrossRefPubMed
69.
Lin MV, Bishop G, Benito-Herrero M: Diabetic ketoacidosis in type 2 diabetics: a novel presentation of pancreatic adenocarcinoma. J Gen Intern Med. 2010, 25: 369-373. 10.1007/s11606-009-1237-9.PubMedCentralCrossRefPubMed
70.
Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J: Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993, 80: 1047-1050. 10.1002/bjs.1800800841.CrossRefPubMed
71.
Chari ST, Zapiach M, Yadav D, Rizza RA: Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology. 2005, 5: 229-233. 10.1159/000085276.CrossRefPubMed
72.
Leighton B, Cooper GJ: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature. 1988, 335: 632-635. 10.1038/335632a0.CrossRefPubMed
73.
Saruc M, Iki K, Pour PM: Morphometric studies in human pancreatic cancer argues against the etiological role of type 2 diabetes in pancreatic cancer. Histol Histopathol. 2010, 25: 423-432.PubMed
74.
Katsumichi I, Pour PM: Diabetes mellitus in pancreatic cancer: is it a causal relationship?. Am J Surg. 2007, 194: S71-S75. 10.1016/j.amjsurg.2007.05.024.CrossRefPubMed
75.
Kolb A, Rieder S, Born D, Giese NA, Giese T, Rudofsky G, Werner J, Büchler MW, Friess H, Esposito I, Kleeff J: Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biol Ther. 2009, 8: 1527-1533.CrossRefPubMed
76.
Aggarwal G, Klee G, Fernandez-Zapico ME, Klee EW, Smyrk TC, Andrade M, Petersen GM, Chari ST: Adrenomedullin: a biomarker of pancreatic cancer-associated diabetes?. Gastroenterology. 2010, 138: S-551-
77.
Sharaf RN, Butte AJ, Montgomery KD, Pai R, Dudley JT, Pasricha PJ: Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes. BMC Gastroenterol. 2011, 11: 5-10.1186/1471-230X-11-5.PubMedCentralCrossRefPubMed
78.
Huang H, Dong X, Kang MX, Xu B, Chen Y, Zhang B, Chen J, Xie QP, Wu YL: Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol. 2010, 105: 1661-1669. 10.1038/ajg.2010.32.CrossRefPubMed
79.
Ding X, Flatt PR, Permert J, Adrian TE: Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998, 114: 130-138. 10.1016/S0016-5085(98)70641-9.CrossRefPubMed
80.
Guo Q, Kang M, Zhang B, Chen Y, Dong X, Wu Y: Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes. J Cancer Res Clin Oncol. 2010, 136: 1627-1631. 10.1007/s00432-010-0820-0.CrossRefPubMed
81.
Sookwong P, Nakagawa K, Fujita I, Shoji N, Miyazawa T: Amadori-glycated phosphatidylethanolamine, a potential marker for hyperglycemia, in streptozotocin-induced diabetic rats. Lipids. 2011, 46: 943-952. 10.1007/s11745-011-3588-3.CrossRefPubMed
82.
Eitsuka T, Nakagawa K, Ono Y, Tatewaki N, Nishida H, Kurata T, Shoji N, Miyazawa T: Amadori-glycated phosphatidylethanolamine up-regulates telomerase activity in PANC-1 human pancreatic carcinoma cells. FEBS Lett. 2012, 586: 2542-2547. 10.1016/j.febslet.2012.06.027.CrossRefPubMed
83.
Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M: Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med. 2009, 47: 713-723.CrossRefPubMed
84.
Fukamachi K, Tanaka H, Hagiwara Y, Ohara H, Joh T, Iigo M, Alexander DB, Xu J, Long N, Takigahira M, Yanagihara K, Hino O, Saito I, Tsuda H: An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. Biochem Biophys Res Commun. 2009, 390: 636-641. 10.1016/j.bbrc.2009.10.019.CrossRefPubMed
85.
Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST: Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 2007, 102: 2157-2163. 10.1111/j.1572-0241.2007.01480.x.CrossRefPubMed
86.
Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS: Associated with insulin glargine among adult type 2 diabetes patients - a nationwide cohort study. PLoS One. 2011, 6: e21368-10.1371/journal.pone.0021368.PubMedCentralCrossRefPubMed
87.
Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC: The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J Cell Mol Med. 2011, 15: 825-836. 10.1111/j.1582-4934.2010.01083.x.PubMedCentralCrossRefPubMed
88.
Chagpar RB, Martin RC, Ahmad SA, Kim HJ, Rupp C, Weber S, Ebelhar A, Gilbert J, Brinkman A, Winslow E, Cho CS, Kooby D, Chu CK, Staley CA, McMasters KM, Scoggins CR: Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. J Gastrointest Surg. 2011, 15: 551-557. 10.1007/s11605-011-1448-3.CrossRefPubMed
89.
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011, 11: 20-10.1186/1471-2407-11-20.PubMedCentralCrossRefPubMed
90.
Becker S, Dossus L, Kaaks R: Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009, 115: 86-96. 10.1080/13813450902878054.CrossRefPubMed
91.
Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009, 52: 1766-1777. 10.1007/s00125-009-1440-6.CrossRefPubMed
92.
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006, 66: 10269-10273. 10.1158/0008-5472.CAN-06-1500.CrossRefPubMed
93.
Rozengurt E, Sinnett-Smith J, Kisfalvi K: Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010, 16: 2505-2511. 10.1158/1078-0432.CCR-09-2229.PubMedCentralCrossRefPubMed
94.
Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E: Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009, 69: 6539-6545. 10.1158/0008-5472.CAN-09-0418.PubMedCentralCrossRefPubMed
95.
Nath SD, Habib SL, Abboud HE: Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005, 293: 2210-2211.PubMed
Metadata
Title
The bidirectional interation between pancreatic cancer and diabetes
Authors
Junhui Li
Gang Cao
Qingyong Ma
Han Liu
Wei Li
Liang Han
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-171

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue

Case report

A case report of an ampullary tumor presenting with spontaneous perforation of an aberrant bile duct and treated with total laparoscopic pancreaticoduodenectomy

Research

Skin-sparing mastectomy and immediate latissimus dorsi flap reconstruction: a retrospective analysis of the surgical and patient-reported outcomes

Research

Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients

Research

Histological features of the gastric mucosa in children with primary bile reflux gastritis

Retraction Note

Retraction Note: colon and rectal surgery for cancer without mechanical bowel preparation: one-center randomized prospective trial

Case report

Synchronous adenocarcinomas of the colon presenting as synchronous colocolic intussusceptions in an adult